These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 731241)

  • 1. Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
    Rappelli A; Glorioso N; Tedde R; Dessi'-Fulgheri P; Monaco F
    J Neurol Neurosurg Psychiatry; 1978 Oct; 41(10):915-8. PubMed ID: 731241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmatic renin activity in patients treated with L-dopa and inhibitor of dopa decarboxylase (IDC).
    Allain H; Van den Driessche J; Bentue-Ferrer D; Reymann JM; Pape D; Madigand M
    Psychopharmacology (Berl); 1979 Mar; 61(2):197-202. PubMed ID: 108737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition.
    Sachs C; Berglund B; Kaijser L
    Acta Neurol Scand; 1985 Jan; 71(1):37-42. PubMed ID: 3976351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 11(5):329-77. PubMed ID: 782834
    [No Abstract]   [Full Text] [Related]  

  • 7. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
    Battistin L; Meneghetti G; Rigotti S; Saia A
    Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the renin-angiotensin-aldosterone system by L-dopa with and without inhibition of extracerebral dopa decarboxylase in man.
    Barbieri C; Caldara R; Ferrari C; Crossignani RM; Recchia M
    Clin Sci (Lond); 1981 Aug; 61(2):187-90. PubMed ID: 7021041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
    Boomsma F; van den Meiracker A; Man in 't Veld A; Schalekamp M
    Life Sci; 1995; 57(19):1753-9. PubMed ID: 7475917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
    Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA
    J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with parkinson's disease.
    Leibowitz M; Lieberman A
    Neurology; 1975 Oct; 25(10):917-21. PubMed ID: 52131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
    Lieberman A; Estey E; Gopinathan G; Ohashi T; Sauter A; Goldstein M
    Neurology; 1978 Sep; 28(9 Pt 1):964-8. PubMed ID: 567768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 19. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.